Ryvu Therapeutics SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLSELVT00013
PLN
26.30
0.3 (1.15%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 0%

  • The company has reported losses. Due to this company has reported negative ROE
2

Poor long term growth as Net Sales has grown by an annual rate of 34.58% and Operating profit at -185.63% over the last 5 years

 
3

Flat results in Mar 25

4

Risky -

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 624 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.94

stock-summary
Return on Equity

-174.62%

stock-summary
Price to Book

8.76

Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Mar 2025)
Net Profit:
-25 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.2%
0%
-8.2%
6 Months
-11.74%
0%
-11.74%
1 Year
-36.63%
0%
-36.63%
2 Years
-59.35%
0%
-59.35%
3 Years
-55.8%
0%
-55.8%
4 Years
-55.8%
0%
-55.8%
5 Years
-45.21%
0%
-45.21%

Ryvu Therapeutics SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
34.58%
EBIT Growth (5y)
-185.63%
EBIT to Interest (avg)
-75.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0.29
Tax Ratio
0.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.31
EV to EBIT
-3.48
EV to EBITDA
-3.73
EV to Capital Employed
75.89
EV to Sales
7.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2178.87%
ROE (Latest)
-129.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -33.73% vs 68.87% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 27.92% vs -31.95% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16.90",
          "val2": "25.50",
          "chgp": "-33.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-29.30",
          "val2": "-41.80",
          "chgp": "29.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.70",
          "val2": "1.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.30",
          "val2": "6.70",
          "chgp": "-50.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.30",
          "val2": "-35.10",
          "chgp": "27.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,875.10%",
          "val2": "-1,733.60%",
          "chgp": "-14.15%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 66.31% vs 20.57% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -20.96% vs -9.90% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "78.00",
          "val2": "46.90",
          "chgp": "66.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-135.30",
          "val2": "-107.20",
          "chgp": "-26.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.80",
          "val2": "0.10",
          "chgp": "3,700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "6.70",
          "val2": "-3.60",
          "chgp": "286.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-111.40",
          "val2": "-92.10",
          "chgp": "-20.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,869.60%",
          "val2": "-2,522.00%",
          "chgp": "65.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
16.90
25.50
-33.73%
Operating Profit (PBDIT) excl Other Income
-29.30
-41.80
29.90%
Interest
1.70
1.70
Exceptional Items
3.30
6.70
-50.75%
Consolidate Net Profit
-25.30
-35.10
27.92%
Operating Profit Margin (Excl OI)
-1,875.10%
-1,733.60%
-14.15%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2025 is -33.73% vs 68.87% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 27.92% vs -31.95% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
78.00
46.90
66.31%
Operating Profit (PBDIT) excl Other Income
-135.30
-107.20
-26.21%
Interest
3.80
0.10
3,700.00%
Exceptional Items
6.70
-3.60
286.11%
Consolidate Net Profit
-111.40
-92.10
-20.96%
Operating Profit Margin (Excl OI)
-1,869.60%
-2,522.00%
65.24%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 66.31% vs 20.57% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -20.96% vs -9.90% in Dec 2023

stock-summaryCompany CV
About Ryvu Therapeutics SA stock-summary
stock-summary
Ryvu Therapeutics SA
Pharmaceuticals & Biotechnology
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
Company Coordinates stock-summary
Company Details
Leona Henryka Sternbacha 2 , KRAKOW None : 30-394
stock-summary
Tel: 48 12 314020048 12 2974700
stock-summary
Registrar Details